Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 475-482

  Steinmetz, T ^a   Tschechne, B ^b   Harlin, O ^c   Klement, B ^c   Franzem, M ^d   Wamhoff, J ^e   Tesch, H ^f   Rohrberg, R ^g   Marschner, N ^h  

^a Outpatient Clinic for Oncology and Haematology   (Germany)

^b Klinikum Neustadt am Rübenberge   (Germany)

^c Vifor (International) Inc   (Switzerland)

^d iOMEDICO   (Germany)

^e Oncology Practice   (Germany)

^f Outpatient Clinic Im Pruefling   (Germany)

^g Oncology Outpatient Clinic in Halle/Saale   (Germany)

^h Joint Practice for Interdisciplinary Oncology and Hematology   (Germany)

Author keywords

Anaemia; Cancer induced anaemia; Chemotherapy induced anaemia; Ferric carboxymaltose; Intravenous iron; Iron deficiency

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; HEMOGLOBIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CHILL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; GERMANY; HEMOGLOBIN DETERMINATION; HOT FLUSH; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NAUSEA; PRIORITY JOURNAL; RIGOR; THROMBOEMBOLISM; TREATMENT OUTCOME; XEROSTOMIA;

EID: 84873831349     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds338     Document Type: Article

References (38)

1. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis 2005; 7: 398-402.
2. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
3. Ludwig H, Müldür E, Endler G et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status. Haematologica 2011; 96: 409, Abstract 982.
4. Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-715.
5. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 2001; 28: 60-65.
6. Brownlie T, Utermohlen V, Hinton PS et al. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004; 79: 437-443.
7. Krayenbuehl PA, Battegay E, Breymann C et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118: 3222-3227.
8. Verdon F, Burnand B, Stubi CL et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003; 326: 1124.
9. Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 2008; 25: 12-21.
10. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002; 87: 1209-1221.
11. National Comprehensive Cancer Network Inc. NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia-v.2.2012. http://www. nccn.org/professionals/physician_gls/PDF/anemia.pdf (5 September 2011, date last accessed).
12. Steinmetz HT, Tsamaloukas A, Schmitz S et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010; 19: 261-269.
13. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307.
14. Auerbach M, Silberstein PT, Webb RT et al. Darbepoetin alfa 300 or 500 ug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010; 85: 655-663.
15. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-1618.
16. Hedenus M, Nasman P, Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharm Ther 2008; 33: 365-374.
17. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242.
18. Pedrazzoli P, Farris A, Del PS et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008; 26: 1619-1625.
19. Bohlius J, Schmidlin K, Brillant C et al. Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; 3: CD007303.
20. Khorana AA, Francis CW, Blumberg N et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168: 2377-2381.
21. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist 2011; 16(Suppl 3): 12-18.
22. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43: 258-270.
23. Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116: 4045-4059.
24. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 2010; 116: 522-525.
25. Kim YT, Kim SW, Yoon BS et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 2007; 105: 199-204.
26. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009; 69: 739-756.
27. Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010; 60: 399-412.
28. Evstatiev R, Marteau P, Iqbal T et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-853.
29. WHO. Iron deficiency anaemia - assessment, prevention, and control. A guide for programme managers. NHD/01.3. 2001.
30. Covic A, Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multicentre, open-label, clinical study. Nephrol Dial Transplant 2010; 25: 2722-2730.
31. Kulnigg S, Stoinov S, Simanenkov V et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192.
32. Anker SD, Comin CJ, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
33. Bisbe E, Garcia-Erce JA, Diez-Lobo AI et al. A multicentre comparative study on the efficacy of intravenous ferric carboxymaltose and iron sucrose for correcting preoperative anaemia in patients undergoing major elective surgery. Br J Anaesth 2011; 107: 477-478.
34. Van Wyck DB, Mangione A, Morrison J et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719-2728.
35. Van Wyck DB, Martens MG, Seid MH et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007; 110: 267-278.
36. Seid MH, Derman RJ, Baker JB et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008; 199: 435-437.
37. Ludwig H, Aapro M, Beguin Y et al. Frequent use of blood transfusions in current treatment practice for chemotherapy-induced anaemia counteracts treatment recommendations aiming for fewer transfusions. Haematologica 2011; 96: 407, Abstract 978.
38. Steinmetz T, Totzke U, Schweigert M et al. A prospective observational study of anaemia management in cancer patients - results from the German Cancer Anaemia Registry. Eur J Cancer Care (Engl) 2011; 20: 493-502.